Status: Recruiting
A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism
This trial has a duration of 78 weeks and will include adult participants already on treatment with palopegteriparatide at doses at or greater than 30 mcg/day. All participants will receive subcutaneous palopegteriparatide during the trial and will be individually and progressively titrated to an optimal dose at pre-specified dose levels. The primary purpose of the trial is to provide additional evidence of treatment effect and safety of palopegteriparatide at doses greater than 30 mcg/day in adults with hypoparathyroidism. The trial will be conducted in the US.
Participants needed: 36
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Ascendis Pharma Bone Diseases A/SUpdated: May 4, 2026Locations: 3
Eligibility criteria
Males and females, ≥18 years of age at the time of providing informed consent [+4]
Impaired responsiveness to PTH (pseudohypoparathyroidism), which is characterize... [+16]